# Buhlmann Laboratories AG

- Location (FDA's records): Schönenbuch, CH
- FDA decisions: 5 (1995–2024): 5 510(k) clearances
- Names in FDA's records: Buhlmann Laboratories AG (4); Bühlmann Laboratories AG (1)
- Product codes: NXO (4), CIB (1)
- 510(k) review time since 2016: median 90 days, against 90 for FDA's reviews in the same codes and years (1 of 3 faster)
- Predicates its devices cite: 4 (3 its own); citations of its devices by later devices: 3 (3 its own)
- Recalls linked to its devices: 0 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Firms whose devices it cites most
- Eurospital S.P.A.: 1 (https://510kreport.com/company/eurospital)

## Its most-cited devices
- K191718: Buhlmann fCAL turbo and CALEX Cap (2019), cited by 1
- K181012: BUHLMANN fCAL ELISA (2018), cited by 1
- K190784: BUHLMANN fCAL turbo (2019), cited by 1

## Recent decisions
- K232057: BÜHLMANN fCAL® turbo and CALEX® Cap (Feb 6, 2024)
- K191718: Buhlmann fCAL turbo and CALEX Cap (Sep 24, 2019)
- K190784: BUHLMANN fCAL turbo (Jun 25, 2019)
- K181012: BUHLMANN fCAL ELISA (Jun 4, 2018)
- K954299: Buhlmann Angiostensin II Ria (Oct 19, 1995)

Source page: https://510kreport.com/company/buhlmann-laboratories